Clinical Trial Update: A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis [Phase 3]

View source ↗

Summary

A Phase 3 study of an increased dose of TA-650 in patients with plaque psoriasis and related psoriatic conditions has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Pustular Psoriasis
• Plaque Psoriasis
• Psoriasis Erythrodermic
• Psoriatic Arthritis

Drugs mentioned

• TA-650

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Plaque Psoriasis, Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2017-03-13